Analysts Set $6.80 Price Target for ProQR Therapeutics

Biotech firm receives 'Moderate Buy' consensus rating from Wall Street

Apr. 4, 2026 at 5:48am

Got story updates? Submit your updates here. ›

An extreme close-up of gears, levers, and other heavy industrial banking equipment, conveying the technical complexity and institutional power of the financial sector.As biotech firms navigate the complex financial landscape, the inner workings of the industry's machinery are brought into sharp focus.Cambridge Today

ProQR Therapeutics N.V. (NASDAQ:PRQR) has been given a 'Moderate Buy' consensus rating by eight Wall Street brokerages, with an average 12-month price target of $6.80 per share. The ratings range from a 'Sell' to an 'Outperform' recommendation, reflecting mixed analyst sentiment on the clinical-stage biotech company's prospects.

Why it matters

ProQR is developing a pipeline of RNA-based therapies for severe genetic diseases, including Leber congenital amaurosis and Usher syndrome. The company's stock price has fluctuated over the past year, and these new analyst ratings and price targets provide insight into Wall Street's current view of the firm's future performance and growth potential.

The details

The average $6.80 price target represents significant upside from ProQR's current trading price around $1.71 per share. One analyst has a 'Sell' rating, while another has a 'Hold' recommendation. The remaining six analysts have issued 'Buy' or 'Outperform' ratings on the stock. Factors influencing the mixed analyst views include the company's clinical trial progress, regulatory milestones, and competitive landscape in the rare disease drug development space.

  • ProQR stock opened at $1.71 on Wednesday, April 4, 2026.
  • The company reported Q1 2026 earnings on March 12, 2026.

The players

ProQR Therapeutics N.V.

A clinical-stage biotechnology company developing RNA-based therapies for severe genetic diseases.

Wall Street Zen

An equity research firm that upgraded ProQR from a 'strong sell' to a 'hold' rating.

Oppenheimer

An investment bank that initiated coverage of ProQR with an 'Outperform' rating and $9 price target.

Citigroup

A global financial services firm that reiterated a 'Market Outperform' rating on ProQR stock.

Weiss Ratings

A research firm that maintained a 'Sell (d-)' rating on ProQR.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee

The takeaway

The mixed analyst views on ProQR Therapeutics reflect the inherent risks and uncertainties in the biotech industry, particularly for clinical-stage companies developing treatments for rare genetic disorders. Investors will be closely watching the company's progress in advancing its pipeline and achieving key regulatory milestones in the coming year.